Meta-analysis of 132 early-phase trials (7786 patients) in relapsed or refractory DLBCL: pooled objective response 30.5% and complete response 14.3%, highest with cellular therapies (70.0%); grade 3-4 adverse events 61.5%, treatment-related mortality 0.6%.
Meta-analysisn = 7,786
Spanjaart et al. Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis